中国血液流变学杂志
中國血液流變學雜誌
중국혈액류변학잡지
CHINESE JOURNAL OF HEMORHEOLOGY
2013年
1期
73-75
,共3页
非小细胞肺癌%吉非替尼%靶向治疗%化疗
非小細胞肺癌%吉非替尼%靶嚮治療%化療
비소세포폐암%길비체니%파향치료%화료
non-small cell lung cancer%geftinib%targeted-therapy%chemotherapy
目的观察比较吉非替尼与含铂方案的常规化疗治疗晚期非小细胞肺癌(NSCLC)的疗效.方法选取呼吸科晚期NSCLC患者,常规化疗组22例,吉非替尼组15例,观察治疗效果及不良反应.结果37例可评价疗效的晚期NSCLC患者中,化疗组:CR 0例,PR 4例,SD 8例,PD 10例,缓解率18.18%(4/22),疾病控制率54.55%(12/22);吉非替尼组:CR 1例,PR 5例,SD 7例,PD 2例,缓解率40.00%(6/15),疾病控制率86.67%(13/15);不良反应主要是骨髓抑制、消化道反应及皮疹,在化疗组和吉非替尼组的发生率分别是72.73%、77.27%、13.64%及6.67%、40.00%、66.67%.结论吉非替尼对晚期NSCLC有良好的疗效,且安全性高,为肺癌的治疗提供了新的途径.
目的觀察比較吉非替尼與含鉑方案的常規化療治療晚期非小細胞肺癌(NSCLC)的療效.方法選取呼吸科晚期NSCLC患者,常規化療組22例,吉非替尼組15例,觀察治療效果及不良反應.結果37例可評價療效的晚期NSCLC患者中,化療組:CR 0例,PR 4例,SD 8例,PD 10例,緩解率18.18%(4/22),疾病控製率54.55%(12/22);吉非替尼組:CR 1例,PR 5例,SD 7例,PD 2例,緩解率40.00%(6/15),疾病控製率86.67%(13/15);不良反應主要是骨髓抑製、消化道反應及皮疹,在化療組和吉非替尼組的髮生率分彆是72.73%、77.27%、13.64%及6.67%、40.00%、66.67%.結論吉非替尼對晚期NSCLC有良好的療效,且安全性高,為肺癌的治療提供瞭新的途徑.
목적관찰비교길비체니여함박방안적상규화료치료만기비소세포폐암(NSCLC)적료효.방법선취호흡과만기NSCLC환자,상규화료조22례,길비체니조15례,관찰치료효과급불량반응.결과37례가평개료효적만기NSCLC환자중,화료조:CR 0례,PR 4례,SD 8례,PD 10례,완해솔18.18%(4/22),질병공제솔54.55%(12/22);길비체니조:CR 1례,PR 5례,SD 7례,PD 2례,완해솔40.00%(6/15),질병공제솔86.67%(13/15);불량반응주요시골수억제、소화도반응급피진,재화료조화길비체니조적발생솔분별시72.73%、77.27%、13.64%급6.67%、40.00%、66.67%.결론길비체니대만기NSCLC유량호적료효,차안전성고,위폐암적치료제공료신적도경.
Objective To observe the efficacy of gefitinib and chemotherapy in treatment for advanced NSCLC.Methods 37 cases are selected and divided into two groups,gefitinib group(15 cases) and chemotherapy group(22 cases).Results Chemotherapy group got 18.18% remission rate and 54.55% disease control rate. Gefitinib group got 40.00% remission rate and 86.67% disease control rate.The major adverse reaction were bone marrow suppression,gastrointestinal reaction and skin rash,and the incidence rates were 72.73%,77.27%,13.64%in chemotherapy group and 6.67%,40.00%,66.67% in gefitinib group,respectively.Conclusion Gefitinib showed better efficacy and with less side effect.It is an effective treatment option for advanced NSCLC.
